Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGGT003 in Hemophilia A
NCT06238908Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NGGT003 in hemophilia A, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Adverse events (AEs) and serious adverse events (SAEs) at 52 weeks and Annualized Bleeding Rate at 52 weeks. Started Jan 2024; status: recruiting.
02
Drugs
NGGT003
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06238908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238908.